Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | PAM | P19021 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442013 | 0.90 | CTRB1 (0.55) | CTRB1LMNACTSSCTSKPAM | |
| SCHEMBL7434134 | 0.90 | CTRB1 (0.55) | CTRB1LMNACTSSCTSKPAM | |
| SCHEMBL7270681 | 0.86 | CTRB1 (0.58) | CTRB1LMNACTSSCTSKPAM | |
| SCHEMBL3134765 | 0.84 | CTSC (0.56) | CTRB1ALPIPKMPTGS1XIAP | |
| SCHEMBL10693913 | 0.83 | CTRB1 (0.49) | CTRB1LMNACTSSCTSKPAM | |
| SCHEMBL24078873 | 0.83 | CTRB1 (0.58) | CTRB1LMNACTSSCTSKPAM | |
| SCHEMBL14866005 | 0.82 | CTRB1 (0.54) | CTRB1LMNACTSSCTSKPAM | |
| SCHEMBL19954666 | 0.82 | CTRB1 (0.54) | CTRB1LMNACTSSCTSKPAM | |
| SCHEMBL7438864 | 0.81 | ACACB (0.56) | CTRB1ACACB | |
| SCHEMBL14865952 | 0.81 | CTRB1 (0.53) | CTRB1LMNACTSSCTSKPAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7169932-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | CTRB1 92/4885LMNA 1755/4885CTSS 18/4885 |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | SERPINB1, PEPD, PREP | CTRB1 87/4885LMNA 1767/4885CTSS 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.